NDAORALTABLET, EXTENDED RELEASE
Approved
Jun 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MUCINEX D is an oral extended-release combination tablet containing guaifenesin (expectorant) and pseudoephedrine HCl (decongestant) used to treat cough and nasal congestion associated with colds and respiratory conditions. The guaifenesin component works by thinning mucus to make coughs more productive, while pseudoephedrine reduces nasal swelling. This is an over-the-counter (OTC) product targeting symptomatic relief in the cold and cough category.
LOE Approaching
As an OTC product approaching loss of exclusivity with moderate competitive pressure (30%), this brand faces declining margins and may signal smaller commercial teams focused on cost management and generic transition planning.
Mechanism of Action
Pharmacologic Class:
Expectorant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions
Started Dec 2014
80 enrolled
Healthy
Career Relevance
Working on MUCINEX D offers limited career growth potential given the product's approaching loss of exclusivity, mature market position, and minimal linked job openings. This role is best suited for professionals seeking stable, operational work in a commoditized OTC category or those building experience in generic transition and cost management strategies.
Brand Manager
Worked on MUCINEX D at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.